Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi Sells 3,829 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,829 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $3.26, for a total transaction of $12,482.54. Following the sale, the chief technology officer now owns 1,749,541 shares of the company’s stock, valued at $5,703,503.66. This trade represents a 0.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

David Badawi also recently made the following trade(s):

• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The shares were sold at an average price of $3.52, for a total value of $10,950.72.

Sight Sciences Trading Down 2.1 %

NASDAQ SGHT opened at $3.25 on Friday. The stock has a 50-day moving average of $3.82 and a 200-day moving average of $5.52. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36. Sight Sciences, Inc. has a 1-year low of $3.16 and a 1-year high of $8.45. The firm has a market cap of $164.95 million, a PE ratio of -3.19 and a beta of 2.57.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $20.16 million for the quarter, compared to the consensus estimate of $20.41 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. As a group, sell-side analysts forecast that Sight Sciences, Inc. will post -1.01 EPS for the current year.

Institutional Trading of Sight Sciences

Large investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its holdings in Sight Sciences by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after buying an additional 12,709 shares during the period. State Street Corp boosted its holdings in Sight Sciences by 17.4% in the third quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after acquiring an additional 95,843 shares in the last quarter. Long Focus Capital Management LLC raised its holdings in Sight Sciences by 86.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock worth $3,739,000 after purchasing an additional 260,594 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Sight Sciences by 46.3% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock worth $1,310,000 after purchasing an additional 65,767 shares during the period. Finally, B. Riley Wealth Advisors Inc. boosted its stake in shares of Sight Sciences by 5.4% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock valued at $1,174,000 after purchasing an additional 10,000 shares in the last quarter. 55.51% of the stock is owned by institutional investors.

Analyst Ratings Changes

SGHT has been the subject of several recent analyst reports. UBS Group initiated coverage on shares of Sight Sciences in a research note on Friday, December 6th. They set a “buy” rating and a $5.50 price objective for the company. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research report on Friday, November 8th. Piper Sandler reissued a “neutral” rating and issued a $5.50 price target (down previously from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Lake Street Capital downgraded shares of Sight Sciences from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $10.00 to $5.00 in a report on Monday, November 4th. Finally, Morgan Stanley reduced their target price on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Monday, November 11th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Sight Sciences has an average rating of “Hold” and a consensus target price of $5.12.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.